Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oral Triferic and Fer-In-Sol with Shohl's Solution in Healthy Volunteers
NCT02767128Phase 1Completed
- Sponsor
- Rockwell Medical
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric pyrophosphate in iron-refractory iron deficiency anemia (IRIDA), sponsored by Rockwell Medical. Primary endpoint: Maximum Plasma Concentration at 24 hours. Started Apr 2016; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
iron-refractory iron deficiency anemia (IRIDA)
Beyond the preview
Go deeper on NCT02767128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767128.